Cargando…
Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution
BACKGROUND: Borderline resectable pancreatic cancer (BRPC) is a category of pancreatic cancer that is anatomically widely spread, and curative resection is uncommon with upfront surgery. Intensity-modulated radiation therapy (IMRT) is a form of radiation therapy that delivers precise radiation to a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800301/ https://www.ncbi.nlm.nih.gov/pubmed/35093003 http://dx.doi.org/10.1186/s12885-022-09244-6 |
_version_ | 1784642230508584960 |
---|---|
author | Masui, Toshihiko Nagai, Kazuyuki Anazawa, Takayuki Sato, Asahi Uchida, Yuichiro Nakano, Kenzo Yogo, Akitada Kaneda, Akihiro Nakamura, Naoto Yoshimura, Michio Mizowaki, Takashi Uza, Norimitsu Fukuda, Akihisa Matsumoto, Shigemi Kanai, Masashi Isoda, Hiroyoshi Mizumoto, Masaki Seo, Satoru Hata, Koichiro Taura, Kojiro Kawaguchi, Yoshiya Takaori, Kyoichi Uemoto, Shinji Hatano, Etsuro |
author_facet | Masui, Toshihiko Nagai, Kazuyuki Anazawa, Takayuki Sato, Asahi Uchida, Yuichiro Nakano, Kenzo Yogo, Akitada Kaneda, Akihiro Nakamura, Naoto Yoshimura, Michio Mizowaki, Takashi Uza, Norimitsu Fukuda, Akihisa Matsumoto, Shigemi Kanai, Masashi Isoda, Hiroyoshi Mizumoto, Masaki Seo, Satoru Hata, Koichiro Taura, Kojiro Kawaguchi, Yoshiya Takaori, Kyoichi Uemoto, Shinji Hatano, Etsuro |
author_sort | Masui, Toshihiko |
collection | PubMed |
description | BACKGROUND: Borderline resectable pancreatic cancer (BRPC) is a category of pancreatic cancer that is anatomically widely spread, and curative resection is uncommon with upfront surgery. Intensity-modulated radiation therapy (IMRT) is a form of radiation therapy that delivers precise radiation to a tumor while minimizing the dose to surrounding normal tissues. Here, we conducted a phase 2 study to estimate the curability and efficacy of neoadjuvant chemoradiotherapy using IMRT (NACIMRT) for patients with BRPC with arterial abutment (BRPC-A). METHODS: A total of 49 BRPC-A patients were enrolled in this study and were treated at our hospital according to the study protocol between June 2013 and March 2021. The primary endpoint was microscopically margin-negative resection (R0) rates and we subsequently analyzed safety, histological effect of the treatment as well as survivals among patients with NACIMRT. RESULTS: Twenty-nine patients (59.2%) received pancreatectomy after NACIMRT. The R0 rate in resection patients was 93.1% and that in the whole cohort was 55.1%. No mortality was encountered. Local therapeutic effects as assessed by Evans classification showed good therapeutic effect (Grade 1, 3.4%; Grade 2a, 31.0%; Grade 2b, 48.3%; Grade 3, 3.4%; Grade 4, 3.4%). Median disease-free survival was 15.5 months. Median overall survival in the whole cohort was 35.1 months. The only independent prognostic pre-NACIMRT factor identified was serum carbohydrate antigen 19–9 (CA19-9) > 400 U/ml before NACIMRT. CONCLUSIONS: NACIMRT showed preferable outcome without significant operative morbidity for BRPC-A patients. NACIMRT contributes to good local tumor control, but a high initial serum CA19-9 implies poor prognosis even after neoadjuvant treatment. TRIAL REGISTRATION: UMIN-CTR Clinical Trial: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011776 Registration number: UMIN000010113. Date of first registration: 01/03/2013, |
format | Online Article Text |
id | pubmed-8800301 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88003012022-02-02 Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution Masui, Toshihiko Nagai, Kazuyuki Anazawa, Takayuki Sato, Asahi Uchida, Yuichiro Nakano, Kenzo Yogo, Akitada Kaneda, Akihiro Nakamura, Naoto Yoshimura, Michio Mizowaki, Takashi Uza, Norimitsu Fukuda, Akihisa Matsumoto, Shigemi Kanai, Masashi Isoda, Hiroyoshi Mizumoto, Masaki Seo, Satoru Hata, Koichiro Taura, Kojiro Kawaguchi, Yoshiya Takaori, Kyoichi Uemoto, Shinji Hatano, Etsuro BMC Cancer Research BACKGROUND: Borderline resectable pancreatic cancer (BRPC) is a category of pancreatic cancer that is anatomically widely spread, and curative resection is uncommon with upfront surgery. Intensity-modulated radiation therapy (IMRT) is a form of radiation therapy that delivers precise radiation to a tumor while minimizing the dose to surrounding normal tissues. Here, we conducted a phase 2 study to estimate the curability and efficacy of neoadjuvant chemoradiotherapy using IMRT (NACIMRT) for patients with BRPC with arterial abutment (BRPC-A). METHODS: A total of 49 BRPC-A patients were enrolled in this study and were treated at our hospital according to the study protocol between June 2013 and March 2021. The primary endpoint was microscopically margin-negative resection (R0) rates and we subsequently analyzed safety, histological effect of the treatment as well as survivals among patients with NACIMRT. RESULTS: Twenty-nine patients (59.2%) received pancreatectomy after NACIMRT. The R0 rate in resection patients was 93.1% and that in the whole cohort was 55.1%. No mortality was encountered. Local therapeutic effects as assessed by Evans classification showed good therapeutic effect (Grade 1, 3.4%; Grade 2a, 31.0%; Grade 2b, 48.3%; Grade 3, 3.4%; Grade 4, 3.4%). Median disease-free survival was 15.5 months. Median overall survival in the whole cohort was 35.1 months. The only independent prognostic pre-NACIMRT factor identified was serum carbohydrate antigen 19–9 (CA19-9) > 400 U/ml before NACIMRT. CONCLUSIONS: NACIMRT showed preferable outcome without significant operative morbidity for BRPC-A patients. NACIMRT contributes to good local tumor control, but a high initial serum CA19-9 implies poor prognosis even after neoadjuvant treatment. TRIAL REGISTRATION: UMIN-CTR Clinical Trial: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011776 Registration number: UMIN000010113. Date of first registration: 01/03/2013, BioMed Central 2022-01-29 /pmc/articles/PMC8800301/ /pubmed/35093003 http://dx.doi.org/10.1186/s12885-022-09244-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Masui, Toshihiko Nagai, Kazuyuki Anazawa, Takayuki Sato, Asahi Uchida, Yuichiro Nakano, Kenzo Yogo, Akitada Kaneda, Akihiro Nakamura, Naoto Yoshimura, Michio Mizowaki, Takashi Uza, Norimitsu Fukuda, Akihisa Matsumoto, Shigemi Kanai, Masashi Isoda, Hiroyoshi Mizumoto, Masaki Seo, Satoru Hata, Koichiro Taura, Kojiro Kawaguchi, Yoshiya Takaori, Kyoichi Uemoto, Shinji Hatano, Etsuro Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution |
title | Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution |
title_full | Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution |
title_fullStr | Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution |
title_full_unstemmed | Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution |
title_short | Impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase II study in a single institution |
title_sort | impact of neoadjuvant intensity-modulated radiation therapy on borderline resectable pancreatic cancer with arterial abutment; a prospective, open-label, phase ii study in a single institution |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800301/ https://www.ncbi.nlm.nih.gov/pubmed/35093003 http://dx.doi.org/10.1186/s12885-022-09244-6 |
work_keys_str_mv | AT masuitoshihiko impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT nagaikazuyuki impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT anazawatakayuki impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT satoasahi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT uchidayuichiro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT nakanokenzo impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT yogoakitada impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT kanedaakihiro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT nakamuranaoto impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT yoshimuramichio impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT mizowakitakashi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT uzanorimitsu impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT fukudaakihisa impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT matsumotoshigemi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT kanaimasashi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT isodahiroyoshi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT mizumotomasaki impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT seosatoru impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT hatakoichiro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT taurakojiro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT kawaguchiyoshiya impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT takaorikyoichi impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT uemotoshinji impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution AT hatanoetsuro impactofneoadjuvantintensitymodulatedradiationtherapyonborderlineresectablepancreaticcancerwitharterialabutmentaprospectiveopenlabelphaseiistudyinasingleinstitution |